Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187061
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gutierrez, Antonio | - |
dc.contributor.author | Bento, Leyre | - |
dc.contributor.author | Novelli, Silvana | - |
dc.contributor.author | Martin, Alejandro | - |
dc.contributor.author | Gutierrez, Gonzalo | - |
dc.contributor.author | Queralt Salas, Maria | - |
dc.contributor.author | Bastos Oreiro, Mariana | - |
dc.contributor.author | Perez, Ariadna | - |
dc.contributor.author | Hernani, Rafael | - |
dc.contributor.author | Cruz Viguria, Maria | - |
dc.contributor.author | López Godino, Oriana | - |
dc.contributor.author | Montoro, Juan | - |
dc.contributor.author | Piñana, Jose | - |
dc.contributor.author | Ferra, Christelle | - |
dc.contributor.author | Parody, Rocio | - |
dc.contributor.author | Martin, Carmen | - |
dc.contributor.author | Español, Ignacio | - |
dc.contributor.author | Yañez, Lucrecia | - |
dc.contributor.author | Rodriguez, Guillermo | - |
dc.contributor.author | Zanabili, Joud | - |
dc.contributor.author | Herrera, Pilar | - |
dc.contributor.author | Varela, Maria | - |
dc.contributor.author | Sampol, Antonia | - |
dc.contributor.author | Solano, Carlos | - |
dc.contributor.author | Caballero, Dolores | - |
dc.contributor.author | On Behalf Of The Grupo Español De Trasplante De Progenitores Hematopoyéticos (geth) And Grupo Español De Linfoma Y Trasplante Autólogo (geltamo) | - |
dc.date.accessioned | 2022-06-27T10:41:00Z | - |
dc.date.available | 2022-06-27T10:41:00Z | - |
dc.date.issued | 2022-05-27 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | http://hdl.handle.net/2445/187061 | - |
dc.description.abstract | Simple Summary We present the long-term results of patients receiving allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory mantle cell lymphoma (R/R MCL) in the last 25 years in Spain. We conclude that allo-SCT may be a curative option in R/R MCL with a low cumulative incidence (CI) of relapse, although non-relapse mortality (NRM) is still high, which is mainly secondary to acute graft-versus-host disease (aGVHD). Results are better for fit patients, using HLA-identical (related or unrelated) or haploidentical related donors and without previous ASCT. However, the arrival of new highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, being administered far away from the optimal timing. Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment. | - |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/cancers14112673 | - |
dc.relation.ispartof | Cancers, 2022, vol. 14, num. 11 | - |
dc.relation.uri | https://doi.org/10.3390/cancers14112673 | - |
dc.rights | cc by (c) Gutierrez, Antonio et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Trasplantament d'òrgans | - |
dc.subject.classification | Limfomes | - |
dc.subject.other | Transplantation of organs | - |
dc.subject.other | Lymphomas | - |
dc.title | Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-06-27T09:47:12Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35681653 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cancers-14-02673.pdf | 1.72 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License